Johnson & Johnson is a dividend king stock whose strong product line and consistency has earned it a listing on the Dow Jones ...

The current earnings multiple is quite low if you take out non-recurring items (NRI). The company now has two operating engines after spinning off consumer brand Kenvue in 2023. Those businesses ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

We recently published a list of 13 Best Cheap Stocks to Invest in for Beginners. In this article, we are going to take a look ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Discover why Genmab's antibody platforms, growing royalties, and late-stage pipeline make it a top biotech stock for ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Johnson & Johnson (NYSE:JNJ) from ...

A history of consistent dividend increases For a strong and steady performance in a healthcare or medical sector stock, JNJ has fared very well. A $25,000 investment in JNJ in 2005 would be ...

BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ETCompany ParticipantsJohn Reed - Executive Vice ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...